CLDF Title
Home | Contact Us | Bookmark
NASH HCC
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: Dova Pharma's thrombocytopenia drug gets FDA approval

Dova Pharma's thrombocytopenia drug gets FDA approval

Last Updated: 2018-05-21

By Reuters Staff

(Reuters) - The U.S Food and Drug Administration said on Monday it had approved Dova Pharmaceuticals Inc's oral drug to treat thrombocytopenia in chronic liver disease (CLD) patients who are scheduled to undergo a medical or dental procedure.

The drug, avatrombopag (Doptelet), belongs to a class of treatments called thrombopoietin receptor agonists (TPO RA), which stimulate platelet production, and is the first such treatment to be approved by the FDA for CLD patients.

A platelet transfusion is commonly recommended for thrombocytopenia patients undergoing procedures with risk of bleeding.

"This drug may decrease or eliminate the need for platelet transfusions, which are associated with risk of infection and other adverse reactions," said Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

According to a statement from Dova, "Two global Phase 3, double-blind, placebo-controlled trials . . . in adults with thrombocytopenia (platelet count of less than 50,000/ L) and CLD, supported FDA approval."

Japan-based Shionogi & Co Ltd is developing a similar drug and an FDA decision is due by late August.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.